Literature DB >> 9878184

Suppression of experimental autoimmune encephalomyelitis by tyrphostin AG-556.

T Brenner1, E Poradosu, D Soffer, C Sicsic, A Gazit, A Levitzki.   

Abstract

Tyrosine kinase blockers from the AG 126/AG-556 tyrphostin family are shown to inhibit the lipopolysaccharide (LPS)-induced production of tumor necrosis factor alpha (TNFalpha), nitric oxide (NO), and prostaglandin E2 (PGE2) in primary rat astrocytes cultures. The tyrphostin AG-556 which was previously shown to be effective against sepsis in mice and dogs also show excellent efficacy in inhibiting experimental autoimmune encephalomyelitis (EAE) in mice. AG-556 does not block the activation of JNK/SAPK and of p38/HOG and therefore seems to act at a target down stream to these kinases which is activated in stress or at a target on an obligatory parallel pathway. These findings together with previous results showing inhibition of sepsis in mice and dogs suggest that protein tyrosine kinase (PTK) blockers of the AG-556 family may be considered in the management of human autoimmune disorders such as multiple sclerosis (MS). Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9878184     DOI: 10.1006/exnr.1998.6971

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  2 in total

1.  Tyrosine kinase inhibition reduces inflammation in the acute stage of experimental pneumococcal meningitis.

Authors:  Klemens Angstwurm; Uwe-Karsten Hanisch; Tarraneh Gassemi; Margrethe Bastholm Bille; Marco Prinz; Ulrich Dirnagl; Helmut Kettenmann; Joerg R Weber
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

2.  Differential effects of tyrosine kinase inhibitors on volume-sensitive chloride current in human atrial myocytes: evidence for dual regulation by Src and EGFR kinases.

Authors:  Xin-Ling Du; Zhan Gao; Chu-Pak Lau; Shui-Wah Chiu; Hung-Fat Tse; Clive M Baumgarten; Gui-Rong Li
Journal:  J Gen Physiol       Date:  2004-03-15       Impact factor: 4.086

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.